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Abstract
Background: The effect of  hepatitis B virus (HBV) infection on fatty liver disease is unclear..
Objectives: The aim of  this study was to investigate the viral and host causes of  fatty liver in chronic hepatitis B (CHB) 
patients. This study included 88 CHB patients of  which 17 were not treated. Liver biopsy was performed in each patient. 
Group 1 included  those with hepatic steatosis (n=28) and group 2 those without hepatic steatosis. The groups were com-
pared in terms of  age, body mass index (BMI), Homeostasis Model Assessment- Insulin Resistance (HOMA-IR), viral load, 
biochemical parameters and histological findings. Patients in  group 1 were subdivided according to the degree of  steatosis 
as follows: grade 1 (15 patients, 53.6%), grade 2 (6 patients, 21.4%),and grade 3 (7 patients, 25%).
Results: In group 1 (n=28), mean age, BMI, cholesterol, and HOMA-IR were found to be significantly higher than in group 
2 (n=60). There were no significant differences in the positivity of  viral load, HbeAg, treatment, fibrosis and other labora-
tory parameters between the two groups. HOMA-IR was the only independent predictive factor of  liver steatosis in patients 
with CHB in logistic regression analysis.
Conclusion:  Hepatic steatosis in CHB patients was associated with host metabolic factors.
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Introduction
Hepatic steatosis (HS) and chronic viral hepatitis are 
both common causes of  chronic liver disease. Chronic 
hepatitis B is a major cause of  liver disease. Most recent 
estimates indicate that 350 million patients are chroni-
cally infected with hepatitis B virus (HBV), worldwide1. 
HS is defined as fat deposition in the liver that exceeds 
5% of  the gross total weight of  the liver, or with more 
than 5% of  hepatocytes containing fat deposits based 
on microscopic examination2. Many agents are capable 
of  inducing HS. Most common cause include drugs, 
toxins, infections, and metabolic alterations. Non- alco-
holic fatty liver disease (NAFLD) is another common 
chronic liver disease that affects more than a quarter  of  
the general population and has been strongly associated 
with obesity and metabolic syndrome. Insulin resistance 
(IR) and metabolic syndrome have also been linked to 
liver disease3. 
Previous studies have clearly demonstrated that hep-
atitis C infection is associated with HS. Moreover the 
relationship between HS and hepatitis C genotype 3 
is well established4. The prevalence of  HS in patients 
with chronic hepatitis C(CHC) ranges from 35%-81%5. 
Host metabolic factors and the direct cytopathic effect 
of  hepatitis C virus(HCV) have been shown to be sig-
nificant risk factors for HS6, although the association 
between HBV and HS remains unclear. Numerous large 
series have failed to demonstrate that there is an asso-
ciation between HS and CHB7,8 whereas some studies 
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have shown that HS in CHB patients  is associated with 
the co-presence of  metabolic syndrome9-11.
This study aimed to investigate the histological preva-
lence of  HS in CHB patients undergoing liver biopsy, 
and to investigate the association of  clinical data, IR, 
severity of  liver fibrosis, and necroinflammation with 
the degree of  occurence. We also examined the factors 
associated with HS and their interaction with viral fac-
tors in CHB patients.
 
Materials and methods
The study included 88 patients with CHB that un-
derwent liver biopsy for diagnostic purposes during a 
2-year period. The HS group included 28 patients and 
the non-HS group included 60 patients. In all cases the 
diagnosis of  CHB was based on the presence of  serum 
HBsAg , elevated liver transaminase for >6 months, 
and/or HBV DNA more than 10000 copies/ml. Pa-
tients taking hepatotoxic drugs that could potentially 
cause steatosis, those that consumed  alcohol regularly, 
those diagnosed with diabetes and cirrhosis, patients 
with anti-HCV, anti-HIV or anti-HDV-antibody posi-
tivity, and those diagnosed with an autoimmune disease 
or other known metabolic liver disease were excluded 
from the study..
Liver biopsy was performed on each patient. Biopsy 
specimens were evaluated by an experienced hepato-
pathologist,blinded to the patient’s clinical data. Biopsy 
specimens were considered adequate if  they  were 1,5 
cm long and/or contained at least 4 to 5 portal tracts. 
Determination of  the histological activity index (HAI) 
and staging of  the biopsy specimens were performed 
according to Knodell’s classification12: HAI was scored 
as portal inflammation (0-4), lobular degeneration (0-4), 
or periportal necrosis (0-10). Grading ranged between 
0-3 points (minimal), 4-8 points (mild), 9-12 points 
(moderate) and 13-18 points (severe). Fibrosis was 
staged separately on a scale of: 0-6, corresponding to 
no fibrosis (0), mild (1-2), moderate (3-4), and severe or 
cirrhosis (5-6). HS was graded according to the Brunt 
classification as13: 0 (no hepatocytes involved with mac-
rovesicular steatosis), 1 (0-33% involved hepatocytes), 
2 (33-66% involved), and 3 (>66% involved hepato-
cytes). In steatosis classification, less than 5% was con-
sidered normal, and ≥5% was considered as steatosis. 
The height and weight of  all patients were measured 
and the BMI was calculated. Based on the BMI, patients 
were classified as normal (BMI=18.5-24.9), over-weight 
(BMI=25-29.9), obese (BMI=30-34.9), or extremely 
obese (BMI= 35-39.9). IR was diagnosed based on the 
homeostasis model assessment (HOMA-IR) method, 
using the following equation: IR (HOMA) = (fasting 
insulin (µU/ml) × fasting glucose (mmol/L))/22.514. 
Laboratory data of  all patients, including liver func-
tion tests, fasting glucose, cholesterol, triglyceride, iron, 
iron binding capacity, ferritin, alpha fetoprotein (AFP), 
insulin, C-peptide, and IGF-1 levels, were also deter-
mined at the time of  liver biopsy.In each patient HBsAg 
and HBeAg were measured using the  macro ELISA 
method, anti-HDV and anti-HIV were measured with 
a micro ELISA method. TaqMan real-time polymer-
ase chain reaction assay was used to measure the HBV 
DNA level.
Statistical analysis
Statistical analysis was performed using SPSS 15.0 for 
Windows. Demographic, biochemical, virological and 
histological parameters were compared between the 
2 groups.. Descriptive data are expressed as median 
(range) or mean (standard deviation). Comparison of  
parametric data between the 2 groups was performed 
using  Student’s t-test. Correlation studies were per-
formed using Pearson’s correlation coefficient. Cate-
gorical variables were compared using the chi-squared 
test. A two-tailed P value < 0.05 was considered statis-
tically significant.
Results
The 88 CHB included in the study were divided into 
the HS group(n=28) and non-HS group (n=60) ac-
cording to  liver biopsy findings (Table 1). Among the 
28 patients in the HS group, 15 (17%) had grade 1, 6 
(7%) grade 2, 7(8%9) grade 3, based on the Brunt clas-
sification. In all, 61 of  the patients were male and 27 
were female and mean age was 31±1.1 years. Among 
the patients, 4 (14%) of  the females and 24 (39%) of  
the males had HS. Male gender was associated with an 
increased risk for HS; the difference between genders 
was significant (p = 0.02).
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Table 1. Demographical, laboratory, metabolic and  virological  features 
of 88 patients univariate analysis with chronic hepatitis B 
 
Variable 
n 60 28   
Mean age(year) 29.2±10.1 36.8±11.0 0.002 
Gender 
(Male/Female) 
37 (61.7)/23 (38.3) 24 (85.7%)/4 (14.3%) 0.02 
BMI       
<25 43 (71.7) 9 (32.1) 0.001 
25-29.9 15 (25.0) 14 (50.0)   
≥30 2 (3.3) 5 (17.9)   
Virological status       
Viral load 3200 copy/ml (0-7x108) 15000 copy/ml (01.1x108) 0.95 
HBeAg(+) 19 (31.7) 9 (32.1) 0.96 
Treatment(+) 14 (23.3) 3 (10.7) 0.16 
ALT 70.5 (15-542) 56 (17-320) 0.74 
AST 43.5 (15-266) 37 (19-150) 0.59 
GGT 28.5 (10-190) 29 (17-499) 0.77 
ALP 77 (33-354) 84 (35-130) 0.77 
Cholesterol 149.1±29.2 168.1±36.8 0.01 
Triglyceride 88 (13-394) 107.5 (43-462) 0.08 
Glucose 86±15.2 97±29.4 0.07 
Insulin 5.9 (1.2-49) 7.9 (1.2-802) 0.004 
C-peptide 2.06 (0.6-11.7) 2.18 (0.2-6.2) 0.63 
IGF-1 125 (31-431) 122 (45-262) 0.53 
HOMA-IR 1.16 (0.25-5.6) 1.8 (0.14-5.37) 0.004 
 
Mean age, BMI, cholesterol, and average HOMA-IR 
levels in the HS group were significantly higher than 
those in the non- HS group. In all, 28 patients were 
HBeAg (+), of  which 9 (33%) patients had HS. 60 pa-
tients were HBeAg (-) and 28 were  HBeAg (+). In to-
tal, 19 (32%) of  the HBeAg (-) patients and 9(33%) of  
the HBeAg (+) patients had HS. Hepatitis serologies 
were not different between the HS and non-HS groups 
(P>0.05). 
Necroinflammatory activity and fibrosis staging were 
not associated with HS. Among all the patients,  17 
received treatment for CHB, of  which 3 had HS, and. 
71 patients were untreated, of  which 25 had HS. The 
difference in HS occurrence between the treated and 
untreated was not significant. Logistic regression anal-
ysis utilizing age, sex, BMI, cholesterol and HOMA-IR 
as variables revealed that only HOMA-IR (OR=1.66, 
95% CI: 1.0-2.7) was significantly and independently 
predictive of  hepatic steatosis in patients with Chronic 
hepatitis B (Table 2).
Table 2. Multivariate logistic regression analysis for hepatic steatosis in patients with 
Chronic hepatitis B  
 
  OR 95%Cl P 
Age 1.04 0.99-1.1 0.09 
Sex 2.48 0.63-9.75 0.19 
BMI 1.12 0.96-1.3 0.14 
Cholesterol 1.02 0.99-1.04 0.062 
HOMA-IR 1.66 1.0-2.7 0.041 
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Discussion
In the present study, it was found that presence of  ste-
atosis in CHB patients does not cause a difference re-
garding histopathological findings and HBeAg status is 
not important in the presence of  steatosis. Insulin re-
sistance, which is known to be an important factor for 
steatosis, was identified as the only independent predic-
tor of  hepatic steatosis in CHB patients in this study. 
In recent years, IR has increased in importance and has 
been linked to chronic liver diseases. IR is associated 
with complications similar to those associated with 
chronic HBV and HCV infection, including cirrhosis 
and hepatocellular carcinoma15. In addition, IR is pre-
dictive of  a poor response to antiviral therapy targeting 
HCV16. HCV infection has been associated with the de-
velopment of  IR. Fasting insulin and the HOMA-IR 
score are high in HCV-infected patients17. In HCV 
genotype 3-related HS patients, the, HCV replication 
level has a direct role in the pathogenesis of  HS. On 
the other hand, the association between HBV and HS 
is unclear. Our literature review revealed only a small 
number of  studies on the prevalence of  HS in patients 
with CHB8-11. Wang et al.18 reported that HBV infection 
is not associated with the development of  HS. Other 
studies have indicated  that accumulation of  lipids via 
activated SREBP-1and PPAR   19 is the cause of  HS . 
This aimed to investigate the histological prevalence of  
HS in CHB patients undergoing liver biopsy, and to in-
vestigate the association of  clinical data, IR, degree of  
liver fibrosis, and necroinflammation with the degree 
of  occurrence. We also examined the factors associ-
ated with HS and their interactions with viral factors 
in CHB patients.. One study reported that HS was ob-
served in 27% of  CHB patients20. In the present study 
age , gender, BMI, serum cholesterol, HOMA-IR and 
hypertension were strongly associated with HS. Inter-
estingly HS was more common in male patients. More-
over, viral load and the severity of  HS were not corre-
lated. Furthermore, HS was not correlated with HBeAg 
positivity. Unfortunately, genotyping of  HBV could not 
be conducted in the present study for various reasons. 
Another interesting finding was that triglyceride levels 
were not associated with HS. 
A relationship was observed in the present study be-
tween liver damage and HS in CHB patients. This find-
ing is in agreement with previously reported literature 
21. Moreover , the severity of  HS was not associated 
with the severity of  fibrosis, which is in agreement with 
ɣ 
earlier reports9,22. The primary determinant of  HS in 
the present study was HOMA-IR. HS and non-HS pa-
tients did not have significant differences in the treat-
ments that were provided. Recently Machado et al. and 
Lesmana et al. reported their results on hepatosteatosis 
in CHB. Similar to our study, Machado found that hepa-
tosteatosis was linked to metabolic alterations and was 
lower in rate when compared to hepatitis C patients23. 
Lesmana on the other hand specifically found a correla-
tion with central obesity24. 
The limitations of  the present study are the small num-
ber of  patients and use of  univariate for most analysis. 
Conclusion  
HS was observed in 33% of  cases of  HBV-related 
chronic liver disease. In patients infected with HBV, HS 
was primarly associated with metabolic factors, such as 
obesity, IR, and dyslipidemia rather than viral factors. 
Additional large-scale studies are needed to further 
evaluate the effect of  HS on the outcome of  antiviral 
therapy in CHB patients.
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